Patents Assigned to Bristol-Myers Company
  • Patent number: 5218106
    Abstract: There are disclosed novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides and processes for their preparation. The compounds so produced exhibit therapeutically useful antiviral and, more particularly, anti-HIV effects.
    Type: Grant
    Filed: March 26, 1992
    Date of Patent: June 8, 1993
    Assignee: Bristol-Myers Company
    Inventors: Roman Z. Sterzycki, Muzammil M. Mansuri, John C. Martin
  • Patent number: 5164379
    Abstract: Complexes of sucralfate with alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin or 2-hydroxypropyl beta cyclodextrin are disclosed. Also disclosed are a process for producing complexes and compositions and a method for reducing gastric injury, employing the complexes.
    Type: Grant
    Filed: July 15, 1991
    Date of Patent: November 17, 1992
    Assignee: Bristol-Myers Company
    Inventors: Randy J. Koslo, Vincent J. Farina
  • Patent number: 5130421
    Abstract: There are disclosed novel processes for producing 2',3'-dideoxy-2'3'-didehydronucleosides, for example, 2',3'-dideoxy-2',3'-didehydrothymidine in high yields and on a large scale. The compounds so-produced are useful as antiviral agents, especially as agents effective against the human immunodeficiency viruses (HIV).
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: July 14, 1992
    Assignee: Bristol-Myers Company
    Inventors: John E. Starrett, Jr., Muzammil M. Mansuri, John C. Martin, Carl E. Fuller, Henry G. Howell
  • Patent number: 5126506
    Abstract: There are disclosed novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides and processes for their preparation. The compounds so produced exhibit therapeutically useful antiviral and, more particularly, anti-HIV effects.
    Type: Grant
    Filed: September 13, 1990
    Date of Patent: June 30, 1992
    Assignee: Bristol-Myers Company
    Inventors: Roman Z. Sterzycki, Muzammil M. Mansuri, John C. Martin
  • Patent number: 5120862
    Abstract: There is provided a novel and efficient stereoselective total synthesis of epipodophyllotoxin and related epipodophyllotoxin compounds of the and present invention ##STR1## wherein R.sup.1 and R.sup.2 each are independently hydrogen or (lower)alkoxy, or R.sup.1 ll and R.sup.2, taken together, is methylenedioxy; R.sup.4 and R.sup.6 each are independently hydrogen or (lower)alkoxy; and R.sup.5 is hydrogen or a phenol-protecting group; or an acid addition salt thereof. The present ivnention also provides novel intermediates and processes for the preparation of said intermediates, which are then converted into known antineoplastic agents.
    Type: Grant
    Filed: October 4, 1991
    Date of Patent: June 9, 1992
    Assignee: Bristol-Myers Company
    Inventors: Dolatrai M. Vyas, Paul M. Skonezny
  • Patent number: 5116845
    Abstract: The novel antitumor antibiotic designated herein as BU-3420T is produced by fermentation of Micromonospora chersina strain M956-1 (ATCC 53710). BU-3420T and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: May 4, 1990
    Date of Patent: May 26, 1992
    Assignee: Bristol-Myers Company
    Inventors: Hiroaki Ohkuma, Masataka Konishi, Kiyoshi Matsumoto, Toshikazu Oki, Yutaka Hoshino
  • Patent number: 5114857
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: May 14, 1991
    Date of Patent: May 19, 1992
    Assignee: Bristol-Myers Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5110940
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or trifluoromethyl;R.sup.2,R.sub.3,R.sup.5 and R.sup.6 each are independently hydrogen, halogen C.sub.1-4 alkyl or C.sub.1-4 alkoxy;tet is ##STR2## n is an integer of from 0 to 2, inclusive; A is ##STR3## R.sup.7 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy(lower) alkyl or (2-methoxyethoxy)methyl;X is --OH or .dbd.O; andR.sup.8 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: May 5, 1992
    Assignee: Bristol-Myers Company
    Inventors: Sing-Yuen Sit, John J. Wright
  • Patent number: 5110960
    Abstract: Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.
    Type: Grant
    Filed: October 1, 1990
    Date of Patent: May 5, 1992
    Assignee: Bristol-Myers Company
    Inventors: Toshikazu Oki, Kyoichiro Saitoh, Kozo Tomatsu, Koji Tomita, Masataka Konishi, Takeo Miyaki, Mitsuaki Tsunakawa, Maki Nishio
  • Patent number: 5106996
    Abstract: There are disclosed intermediates which can be converted into podophyllotoxin and related compounds, which are known antineoplastic agents. There are also disclosed processes for the preparation of such intermediates, and processes for the conversion of the intermediates into known intermediates which are readily converted into podophyllotoxin and related compounds.
    Type: Grant
    Filed: July 25, 1990
    Date of Patent: April 21, 1992
    Assignee: Bristol-Myers Company
    Inventors: Takushi Kaneko, Henry S. L. Wong
  • Patent number: 5099016
    Abstract: The present invention provides novel mitomycin analogs containing a disulfide group and processes for the preparation thereof. These compounds are mitomycin A analogs in which the 7-alkoxy group bears an organic substituent incorporating a disulfide group. Mitomycin A is an antibiotic of established utility, and the 7-O-substituted mitosane analogs thereof have similar utility.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: March 24, 1992
    Assignee: Bristol-Myers Company
    Inventors: Dolatrai M. Vyas, Terrence W. Doyle, Richard A. Partyka
  • Patent number: 5097036
    Abstract: The present invention provides novel mitomycin analogs containing a disulfide group and processes for the preparation thereof. These compounds are mitomycin A analogs in which the 7-alkoxy group bears an organic substituent incorporating a disulfide group. Mitomycin A is an antibiotic of established utility, and the 7-O-substituted mitosane analogs thereof have similar utility.
    Type: Grant
    Filed: February 26, 1990
    Date of Patent: March 17, 1992
    Assignee: Bristol-Myers Company
    Inventors: Dolatrai M. Vyas, Terrence W. Doyle, Richard A. Partyka
  • Patent number: 5096817
    Abstract: Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.
    Type: Grant
    Filed: December 14, 1990
    Date of Patent: March 17, 1992
    Assignee: Bristol-Myers Company
    Inventors: Maki Nishio, Yosuke Sawada, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5095011
    Abstract: A stable, amorphous, lyophilized dihydrochloride salt of 7-[.alpha.-(2-aminothiazol-4-yl)-.alpha.-(z)-methoxyiminoacetamido]-3-[(1- methyl-1-pyrrolidinium) methyl]-3-cephem-4-carboxylate is described. This lyophilized salt is more easily prepared than the crystalline counterpart and can be reconstituted in effective concentrations for intramuscular and intravenous injection utilizing suitable organic and inorganic bases to pH 3-7.0.
    Type: Grant
    Filed: December 20, 1990
    Date of Patent: March 10, 1992
    Assignee: Bristol-Myers Company
    Inventors: Murray A. Kaplan, Munir N. Nassar
  • Patent number: 5089526
    Abstract: A process is provided for preventing or ameliorating arrhythmia by administering to mammals, including man, an effective dose of d-sotalol to lengthen the action potential duration of cardiac cell without blockade of beta-adrenergic receptor sites.
    Type: Grant
    Filed: December 23, 1986
    Date of Patent: February 18, 1992
    Assignee: Bristol-Myers Company
    Inventors: Arthur Simon, Jeff A. Thomis
  • Patent number: 5086182
    Abstract: There is provided a novel and efficient stereoselective total synthesis of epiodophyllotoxin and related epipodophyllotoxin compounds of the general formula ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen or (lower)-alkoxy, or R.sup.1 and R.sup.2, taken together, is methylenedioxy; R.sup.4 and R.sup.6 each are independently hydrogen or (lower) alkoxy; and R.sup.5 is hydrogen or a phenol-protecting group; or an acid addition salt thereof. The present invention also provides novel intermediates and processes for the preparation of said intermediates, which are then converted into known antineoplastic agents.
    Type: Grant
    Filed: February 13, 1991
    Date of Patent: February 4, 1992
    Assignee: Bristol-Myers Company
    Inventors: Dolatrai M. Vyas, Paul M. Skonezny
  • Patent number: 5073633
    Abstract: An antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.
    Type: Grant
    Filed: November 5, 1990
    Date of Patent: December 17, 1991
    Assignee: Bristol-Myers Company
    Inventors: Daniel Schroeder, Kin S. Lam, Jacqueline Mattei, Grace A. Hesler
  • Patent number: 5071957
    Abstract: The antibiotic designated BU-4061T is produced by fermentation of actinomycete strain Q996-17 (ATCC-53904). The BU-4061T antibiotic exhibits both in vitro and in vivo antitumor activity.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: December 10, 1991
    Assignee: Bristol-Myers Company
    Inventors: Masataka Konishi, Minoru Hanada, Yuji Nishiyama
  • Patent number: 5070206
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trifluoromethyl;R is hydrogen, C.sub.1-4 alkyl or phenyl;A is ##STR2## R.sup.5 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.
    Type: Grant
    Filed: February 13, 1991
    Date of Patent: December 3, 1991
    Assignee: Bristol-Myers Company
    Inventors: Sing-Yuen Sit, John J. Wright
  • Patent number: 5068346
    Abstract: Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.4 each are independently hydrogen, halogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or trifluoromethyl;R.sup.2, R.sup.3,R.sup.5 and R.sup.6 each are independently hydrogen, halogen C.sub.1-4 alkyl or C.sub.1-4 alkoxy;tet is ##STR2## n is an integer of from 0 to 2, inclusive; A is ##STR3## R.sup.7 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy(lower) alkyl or (2-methoxyethoxy)methyl;X is --OH or .dbd.O; andR.sup.8 is hydrogen, a hydrolyzable ester group or a cation to form a non-toxic pharmaceutically acceptable salt,are novel antihypercholesterolemic agents which inhibit cholesterol biosynthesis. Intermediates and processes for their preparation are disclosed.
    Type: Grant
    Filed: November 17, 1989
    Date of Patent: November 26, 1991
    Assignee: Bristol-Myers Company
    Inventors: Sing-Yuen Sit, John J. Wright